Introducing Verifi™ – Noninvasive Prenatal Screening (NIPS) for expectant mothers
What is noninvasive prenatal screening (NIPS)?
Noninvasive Prenatal Screening (NIPS), often referred to as Noninvasive Prenatal Testing (NIPT), is a screen that helps determine the risk that your child will be born with specific genetic abnormalities.
As your cells break down, the DNA fragments contained within them escape into your bloodstream. These fragments are commonly referred to as cell-free DNA or cfDNA. During pregnancy, your bloodstream contains DNA fragments from both you and your baby. Using NIPS, this DNA provides you with a unique opportunity to assess the risk of genetic abnormalities early so you can avoid potentially harmful procedures like CVS or amniocentesis. With a single blood draw, we can analyze the genetic information contained in your baby’s DNA to screen for chromosomal disorders, helping you make informed decisions about you and your baby’s health.
It’s important to note that NIPS is a screening test which means that the results are not considered a diagnosis – they are an assessment of risk. You should work together with your healthcare provider to interpret the results and decide whether additional tests are necessary.
What conditions are screened for?
NIPS is used to screen for the most common chromosome-based disorders that are caused by either extra chromosomes (trisomy) or missing chromosomes (monosomy). The presence of either is called an aneuploidy. NIPS can also be used to screen for disorders caused by missing segments of specific chromosomes. These are called microdeletion syndromes.
Verifi™ screens for the following:
With Verifi Plus™, you get all of the aneuploidies reported on in Verifi™, with the addition of any of the following:
Who should get noninvasive prenatal screening?
We’re firm believers that all expectant mothers can benefit from NIPS. Our goal is to provide access to healthcare that informs proactive decisions. We believe that that information can help expectant mothers regardless of their risk level.
There are some cases where getting screened is even more important:
- Advanced maternal age (> 35 years)
- Positive serum screen
- Abnormal ultrasound
- History suggestive of increased risk for the specified chromosome aneuploidies
Verifi™ delivers more accurate than maternal serum screening methods for detecting fetal chromosome aneuploidies.
- Available for all pregnant women
- Accurate prenatal insights as early as week 10
- Insights into genetic health risks
- High reported detection rate for Down syndrome
- Low reported false positive rate for Down syndrome
- A broad screening window (performed as early as 10 weeks gestation until term)